A multi-center analysis of BRAF inhibitor resistance combining three comprehensive genome sequencing studies of pre-treatment and post-progression cases of melanoma identified resistance driving events in 58.3% (77/132) of samples obtained from 100 individuals, but failed to identify any known mechanism of resistance in the remaining 41.7% of samples (7). This evidence concerns the gene BRAF and melanoma.